Avanir Settles With Sandoz Over Nuedexta Generic Plans

Law360, New York (August 14, 2013, 3:01 PM EDT) -- Avanir Pharmaceuticals Inc. has settled a suit in Delaware federal court accusing Sandoz Inc.'s planned generic version of involuntary-emotion treatment Nuedexta of infringing three patents, the company announced Wednesday.

Under the terms of the deal, Sandoz will be allowed to sell its generic version of Nuedexta on July 30, 2026, just before the Aug. 13, 2026 expiration of the last patent-in-suit — U.S. Patent Number 7,659,282 — or earlier under certain unspecified circumstances, according to Avanir. The remaining terms of the settlement were not publicly disclosed....
To view the full article, register now.